Home / Health / Kerala's SMA Drug Debate: Costly Original vs. Cheaper Generic
Kerala's SMA Drug Debate: Costly Original vs. Cheaper Generic
26 Jun
Summary
- Kerala faces debate over expensive patented SMA drug versus a cheaper generic.
- Approved generic formulation offers significant cost savings for treatment.
- Public health experts advocate for wider access through generic procurement.
A contentious debate is unfolding in Kerala concerning the procurement of drugs for Spinal Muscular Atrophy (SMA), a severe genetic disorder. Since 2021, the state has been funding the expensive patented drug Risdiplam for free distribution to patients.
Recently, a generic version, Risdinat, approved by national regulatory bodies, became available at a substantially reduced cost. This presents an opportunity for Kerala to expand treatment access and redirect savings to other rare diseases.
Patient advocacy groups have expressed concerns about the generic drug's untested efficacy, urging continued use of the patented molecule. However, public health experts counter that regulatory approval, demonstrating bioequivalence, should be the basis for procurement in public health programs.
Experts highlight that the generic's lower cost would allow treatment for many more SMA patients and support care for other rare conditions, maximizing public health benefits within limited resources.
